SARAH CANNON
Molecular Diagnostics
Part of HCA Healthcare UK
1 Capper Street, London WC1E 6JA
+44 (0)20 3794 1920
info@sarahcannon-md.co.uk
www.sarahcannon-md.co.uk

BRAF CODON 600 VARIANT ANALYSIS

Patient Details		Source Information		Sample Information	
Lab Number:	MP17-5874	Requester Ref:		Date Received:	01/08/2017
Surname:	Atient	Surgical No.:	323/13	Primary Tumour Site:	Skin
Forename:	Peter	Sample Type	FFPE Block	Tumour Subtype:	Nodular Melanoma
D.O.B. (D/M/Y)	10/12/1976	Consultant:	Smith	Tissue Sample Site:	Skin
Gender:	Male	Hospital:	Random DGH	% Tumour (Whole): (Selected):	21-50%

Results

Detected DNA Change: c.1799T>A or c.1799_1800delinsAA

Detected Protein Change: p.(Val600Glu)

Mutation Status Summary:

There is evidence of BRAF p.(Val600Glu) mutation in this sample, this mutation indicates an increased likelihood of response to BRAF-targeted treatment.

Other Comments:

None

Approved by:

Signature:

Name: Dr F. Irst **Date:** 01/08/2017

Job Title:

Clinical Scientist ✔
Consultant Histopathologist
BMS (senior)

Checked by:

Signature:

Name: Dr S. Econd **Date:** 01/08/2017

Job Title:

BMS
Trainee Clinical Scientist
Trainee BMS
Molecular Biology, PhD ✔

This assay was performed on a Qiagen RotorGene-Q QPCR system using the Therascreen BRAF RGQ PCR Kit. This assay is CE-IVD certified for use on samples with >5% tumour content, with an analytical sensitivity of approximately 5% variant frequency and can detect the following mutations; p.Val600Glu (c.1799T>A or c.1799_1800delinsAA), p.Val600Asp (c.1799_1800delinsAT), p.Val600Lys (c.1798_1799delinsAA), and p.Val600Arg (c.1798_1799delinsAG). All DNA and Protein changes are given with respect to BRAF reference sequence NM_004333.4.